Latest research on tasquinimod

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

Latest findings

Some natural compounds, such as psoralidin and FTY720, or chemical compounds, such as non-steroidal anti-inflammatory drugs (NSAIDs) and tasquinimod, possess chemopreventive effects [5–8]. [source, 2015]
In addition, clinical trials with the S100A9 inhibitor, tasquinimod (TasQ), that disrupts S100A9-TLR4 interactions has shown limited efficacy against castrate-resistant prostate cancer [48]. [source, 2015]
In a placebo-controlled, phase II randomized trial, tasquinimod doubled the median progression-free survival (PFS) period and prolonged survival of patients with metastatic CRPC [79, 80]. [source, 2015]
A phase III clinical trial to test the effect of tasquinimod in the same patients population is ongoing (NCT01234311). [source, 2015]
tasquinimod has been shown to inhibit prostate cancer growth and metastasis in animal models [81, 82]. [source, 2015]
More recent data have suggested that tasquinimod may affect HIF by interfering with histone deacetylase 4 (HDAC 4) [84]. [source, 2015]
However, in an orthotopic, metastatic prostate cancer model, tasquinimod reduced the metastatic rate without affecting microvessel density in the primary tumor. [source, 2015]
Therefore, mechanisms other than impairing angiogenesis may play an important role in the antitumor and antimetastasis activities of tasquinimod. [source, 2015]
At this regard, S100A9 has been identified as a potential target of tasquinimod. [source, 2015]
tasquinimod has previously demonstrated potential therapeutic benefit in several xenograft tumor models which has been mainly linked to its anti-angiogenic properties [22]. [source, 2015]